Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06805617 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

Study acronym: I-MAC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 29, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jul 1, 2025 to Jul 1, 2026v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 1, 2025 to Feb 26, 2025
    • Site details revised at 2 of 2 sites
    v3
  3. Secondary endpoints: details revised at 1 of 6 entriesv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers. The name of the study drug involved in this study is: -Ivonescimab (a type of antibody)
Trial Details
NCT Number NCT06805617
Lead Sponsor Glenn J. Hanna
Collaborators: Summit Therapeutics
Conditions
(from sponsor)		 Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer, Adenoid Cystic Carcinoma
Related terms Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov